Literature DB >> 27278216

Expression of organic cation transporter 1 (OCT1): unique patterns of indirect regulation by nuclear receptors and hepatospecific gene regulation.

Lucie Hyrsova1, Tomas Smutny1, Frantisek Trejtnar1, Petr Pavek1.   

Abstract

The organic cation transporter 1 (OCT1) is the dominant carrier of organic cationic drugs and some positively charged endogenous compounds into hepatocytes. OCT1 has unique expression pattern. It has the highest expression among drug transporters in normal human hepatocytes with large interindividual variability, but it has negligible expression in other tissues or their tumors. Nowadays, it is clear that the regulation of SLC22A1 gene encoding OCT1 transporter is rather complex and that transactivation with hepatocyte nuclear factor 4α (HNF4α) and CCAAT-enhancer-binding protein (C/EBPs) transcription factors as well as epigenetic regulation contribute to its unique hepatocyte-specific expression pattern. Unfortunately, species- and tissue-specific regulation of OCT1 and its orthologs as well as significant down-regulation in most immortalized cell lines hamper the study of SLC22A1 gene regulation. In the current review, we summarize our current understanding of human OCT1 transporter hepatic gene regulation and we propose potential post-transcriptional regulation by predicted miRNAs. We also discuss in detail recent findings on indirect regulation of the transporter via farnesoid X receptor (FXR), glucocorticoid receptor and pregnane X (PXR) receptor, which point out to potential novel mechanisms of xenobiotic-transporting and drug-metabolizing proteins regulation in the human liver as well as to potentially novel drug-drug interaction mechanisms. We also propose that comprehensive understanding of mechanisms of SLC22A1 gene regulation could direct research for other drug transporters and drug-metabolizing enzymes highly expressed in hepatocytes and controlled by HNF4α or other liver-enriched transcription factors.

Entities:  

Keywords:  Gene regulation; hepatic uptake; liver; nuclear receptors; organic cation transporter 1; transporter

Mesh:

Substances:

Year:  2016        PMID: 27278216     DOI: 10.1080/03602532.2016.1188936

Source DB:  PubMed          Journal:  Drug Metab Rev        ISSN: 0360-2532            Impact factor:   4.518


  10 in total

Review 1.  Alternative Splicing: Expanding Diversity in Major ABC and SLC Drug Transporters.

Authors:  Ji Eun Park; Gongmi Ryoo; Wooin Lee
Journal:  AAPS J       Date:  2017-10-02       Impact factor: 4.009

2.  Epigenetic events involved in organic cation transporter 1-dependent impaired response of hepatocellular carcinoma to sorafenib.

Authors:  Ruba Al-Abdulla; Elisa Lozano; Rocio I R Macias; Maria J Monte; Oscar Briz; Colm J O'Rourke; Maria A Serrano; Jesus M Banales; Matias A Avila; Maria L Martinez-Chantar; Andreas Geier; Jesper B Andersen; Jose J G Marin
Journal:  Br J Pharmacol       Date:  2019-02-11       Impact factor: 8.739

3.  Metformin and glucose starvation decrease the migratory ability of hepatocellular carcinoma cells: targeting AMPK activation to control migration.

Authors:  Anabela C Ferretti; Florencia Hidalgo; Facundo M Tonucci; Evangelina Almada; Alejandro Pariani; María C Larocca; Cristián Favre
Journal:  Sci Rep       Date:  2019-02-26       Impact factor: 4.379

4.  Role of OCT1 in hepatocellular carcinoma.

Authors:  Jingguo Li; Zhengyi Yang; Biguang Tuo
Journal:  Onco Targets Ther       Date:  2019-07-25       Impact factor: 4.147

Review 5.  Regulation Mechanisms of Expression and Function of Organic Cation Transporter 1.

Authors:  Giuliano Ciarimboli
Journal:  Front Pharmacol       Date:  2021-01-21       Impact factor: 5.810

6.  Functional Genomic Screening in Human Pluripotent Stem Cells Reveals New Roadblocks in Early Pancreatic Endoderm Formation.

Authors:  Jana Krüger; Markus Breunig; Lino Pascal Pasquini; Mareen Morawe; Alexander Groß; Frank Arnold; Ronan Russell; Thomas Seufferlein; Ninel Azoitei; Hans A Kestler; Cécile Julier; Sandra Heller; Meike Hohwieler; Alexander Kleger
Journal:  Cells       Date:  2022-02-08       Impact factor: 6.600

Review 7.  Regulation of Drug Transport Proteins-From Mechanisms to Clinical Impact: A White Paper on Behalf of the International Transporter Consortium.

Authors:  Kim L R Brouwer; Raymond Evers; Elizabeth Hayden; Shuiying Hu; Cindy Yanfei Li; Henriette E Meyer Zu Schwabedissen; Sibylle Neuhoff; Stefan Oswald; Micheline Piquette-Miller; Chitra Saran; Noora Sjöstedt; Jason A Sprowl; Simone H Stahl; Wei Yue
Journal:  Clin Pharmacol Ther       Date:  2022-05-24       Impact factor: 6.903

8.  Loss of organic cation transporter 3 (Oct3) leads to enhanced proliferation and hepatocarcinogenesis.

Authors:  Johanna Vollmar; Anja Lautem; Ellen Closs; Detlef Schuppan; Yong Ook Kim; Daniel Grimm; Jens U Marquardt; Peter Fuchs; Beate K Straub; Arno Schad; Dirk Gründemann; Jörn M Schattenberg; Nadine Gehrke; Marcus A Wörns; Jan Baumgart; Peter R Galle; Tim Zimmermann
Journal:  Oncotarget       Date:  2017-12-18

9.  The farnesoid X receptor agonist obeticholic acid upregulates biliary excretion of asymmetric dimethylarginine via MATE-1 during hepatic ischemia/reperfusion injury.

Authors:  Andrea Ferrigno; Laura Giuseppina Di Pasqua; Clarissa Berardo; Veronica Siciliano; Vittoria Rizzo; Luciano Adorini; Plinio Richelmi; Mariapia Vairetti
Journal:  PLoS One       Date:  2018-01-18       Impact factor: 3.240

10.  PPARα-Dependent Modulation by Metformin of the Expression of OCT-2 and MATE-1 in the Kidney of Mice.

Authors:  Adriano Cleis Arruda; Mauro Sérgio Perilhão; Warley Almeida Santos; Marcos Fernandes Gregnani; Alexandre Budu; José Cesar Rosa Neto; Gabriel Rufino Estrela; Ronaldo Carvalho Araujo
Journal:  Molecules       Date:  2020-01-17       Impact factor: 4.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.